A recently published Phase 3 study in The New England Journal of Medicine reported results from the B-Well 1 and B-Well 2 trials evaluating bepirovirsen, an investigational antisense oligonucleotide, in adults with chronic hepatitis B virus infection. The trials showed that functional cure at week 72 was achieved in a higher proportion of patients receiving bepirovirsen than placebo, with stronger responses observed among patients with lower baseline HBsAg levels. The study also highlights the importance of HBV DNA and HBsAg monitoring in finite-therapy evaluation, NA discontinuation assessment, treatment-response evaluation, and post-treatment follow-up.
Real-world evidence is reshaping how vaginitis care is understood in everyday clinical practice. Based on a recent analysis of more than four million patients presenting with vaginitis symptoms in the United States, this article highlights a major diagnostic-care gap: testing remains underused, empiric prescribing is widespread, and recurrence and repeat visits are common. The findings reinforce the importance of a “diagnose first” approach in women’s reproductive health. Accurate and timely diagnosis can help identify the underlying cause of vaginitis, support more targeted treatment, reduce repeated care, and improve both healthcare equity and resource efficiency.
Most anogenital HPV infections are naturally cleared within two years, yet approximately 10% may persist. A high-temporal-resolution cohort study published in PLOS Biology investigated HPV viral-load kinetics and local immune dynamics in young women through intensive follow-up every two months. The study found that many HPV infections do not follow a simple rise-and-fall pattern, but instead exhibit a prolonged viral-load plateau before clearance. These findings provide new insights into HPV infection dynamics, host-related factors, and immune correlates associated with viral clearance, supporting future research into HPV screening optimization, biomarker discovery, and immune-based intervention strategies.
As the Southern Hemisphere enters its winter respiratory season, healthcare systems are facing renewed pressure from the co-circulation of influenza, SARS-CoV-2, RSV, and other respiratory pathogens. This article reviews the shifting epidemiological landscape across selected Southern Hemisphere regions, the associated economic burden on healthcare systems and households, and the diagnostic limitations of symptom-based triage and rapid antigen testing during high co-circulation periods. It also highlights the role of CE-IVD marked multiplex real-time PCR solutions in supporting broader respiratory pathogen detection, helping laboratories reduce diagnostic uncertainty and strengthen preparedness for complex respiratory seasons.
Human papillomavirus (HPV) DNA testing offers high sensitivity for cervical cancer screening, but its limited specificity can result in unnecessary follow-up procedures. Standardized HPV viral load quantification is emerging as a promising approach to improve risk stratification and triage among HPV-positive individuals. This article reviews the recently published Chinese Expert Consensus on the Use of Human Papillomavirus Viral Load for Cervical Cancer Screening and Triage alongside an international review in Expert Review of Molecular Diagnostics. Both publications emphasize quantitative real-time PCR methods that normalize HPV viral load to sample cellularity using a human single-copy gene as an internal reference. This approach helps reduce sampling bias and enables more reproducible comparisons across specimens. The article also discusses the BioPerfectus BMRT HPV Genotyping Real-Time PCR workflow, which combines extended HR-HPV genotyping with TOP3-based cell quantification, as well as the use of ROC curve analysis to establish clinically relevant viral load cutoffs. Although further multicenter validation and international standardization are required, HPV viral load combined with genotyping may support more precise cervical cancer screening, reduce unnecessary colposcopy referrals, and enable risk-based clinical management.
This article explores the global epidemiology of male HPV and sexually transmitted infections (STIs) in the context of International Men’s Health Week 2026. By reviewing HPV prevalence, regional disparities, anatomical site-specific infection patterns, HPV-associated malignancies, and the broader burden of curable STIs, it highlights the importance of including men in prevention strategies. Gender-neutral vaccination, health education, timely testing, and molecular diagnostics can support more comprehensive STI control and public health prevention efforts.
The 2026 WHO guideline on HPV DNA genotyping clarifies how different genotyping approaches can support cervical cancer screening and the management of HPV-positive women. While HPV DNA testing remains a recommended primary screening method, limited and extended genotyping may help stratify carcinogenic HPV types by risk and support risk-based management. This article summarizes the guideline’s key objectives, HPV risk grouping, and management considerations for settings with different follow-up capacities.
January 2026 marks a watershed moment for women’s health and molecular diagnostics in the United States. The Health Resources and Services Administration (HRSA) has officially updated its Women’s Preventive Services Guidelines to endorse human papillomavirus (HPV) self-collection as a primary screening option—a profound transformation in how the country approaches cervical cancer elimination, shifting the focus toward accessible, molecular-driven public health strategies.
With almost 150,000 new cases and 100,000 deaths per year, cervical cancer associated with high risk‐human papillomavirus (HR‐HPV) constitutes a major public health problem in sub‐Saharan Africa, ranking the second most common cause of female cancer incidence and mortality in African women. HPV DNA detection by molecular biology is now recommended as the primary screening method in cervical cancer prevention. HPV viral load, as a potential biomarker, holds significant value for guiding treatment strategies and predicting clinical outcomes.
Learn about spinal muscular atrophy (SMA) — a genetic neuromuscular disorder caused by SMN1 mutations. Explore its types, diagnosis, and latest SMA treatments including Spinraza, Zolgensma, and Evrysdi.
